Genes reveal which patients will benefit from scleroderma drug

Systemic sclerosis, also known as scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Northwestern University Feinberg School of Medicine and Dartmouth's Geisel School of Medicine, doctors may be able to treat some patients more effectively.

Characterized by thickening of the skin, scleroderma can also cause significant complications in the joints and —particularly the esophagus, lower , lungs, heart and kidneys. There is no cure—and the one drug commonly used to treat the disease, mycophenolate mofetile (MMF) does not work for all patients. In the absence of a to inform therapeutic , patients are exposed to ineffective and potentially toxic medications.

In the first study of its kind in scleroderma, Monique Hinchcliff, M.D., assistant professor of medicine at the Feinberg School, associate director of the Northwestern Scleroderma Program, and a physician at Northwestern Memorial Hospital, and Michael Whitfield, associate professor of genetics at the Geisel School of Medicine, together have shown that signatures can accurately identify patients who will positively respond to a particular therapy.

The paper was recently published electronically in the Journal of Investigative Dermatology.

"There is the potential for adverse reactions including death with scleroderma therapies, and delay in initiating appropriate therapy can be harmful," Hinchcliff said. "Selecting effective treatment for each patient is the major issue facing physicians treating scleroderma patients."

Whitfield's and Hinchcliff's findings revealed that patients whose conditions improve with MMF therapy all share a particular gene expression pattern in skin.

During the clinical trial, patients who improved during MMF therapy were classified in the inflammatory gene expression subset, while patients who did not improve were classified in the normal-like or fibroproliferative gene expression subsets. This fits the initial hypothesis since MMF impairs lymphocyte proliferation.

An MMF response gene expression signature was also identified—the signature was composed of genes whose expression changed significantly during MMF treatment in patients that improved, but was absent in patients that did not improve.

The results of these experiments suggest that analysis of gene expression in skin may allow targeted treatment in patients with scleroderma.

While this is a small pilot study, it represents an important step forward in approaching complex rare diseases, such as scleroderma, where existing therapies show little or no efficacy, notes John Varga, M.D., the John and Nancy Hughes Professor at the Feinberg School and a physician at Northwestern Memorial, who also participated in the study.

If validated in a larger patient cohort now underway, the results will have significant impact on the development of effective treatment strategies for patients with .

More information: The research paper is titled, "Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis." It can be found at: www.nature.com/jid/journal/vao… abs/jid2013130a.html

add to favorites email to friend print save as pdf

Related Stories

Northwestern to explore personalized medicine for scleroderma

Dec 02, 2011

Northwestern Medicine researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study scleroderma, ...

Cancer drug may also work for scleroderma

Sep 22, 2011

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

Researchers discover gene signatures for scleroderma

Jul 16, 2008

Distinct genetic profiles can discern different groups of patients with scleroderma, a vexing autoimmune disease in which the body turns against itself, Dartmouth Medical School researchers report. Their discovery of distinguishing ...

Geneticists hunt for scleroderma triggers

Oct 29, 2009

At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, ...

Recommended for you

Dengue fever strikes models in Japan

1 hour ago

A worsening outbreak of dengue fever in Japan has claimed its first celebrities—two young models sent on assignment to the Tokyo park believed to be its source.

Japanese researchers develop 30-minute Ebola test

1 hour ago

Japanese researchers said Tuesday they had developed a new method to detect the presence of the Ebola virus in 30 minutes, with technology that could allow doctors to quickly diagnose infection.

Senegal monitors contacts of 1st Ebola patient

13 hours ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

19 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

Sep 01, 2014

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments